In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Bruce the dog reviews cultivated meat
In Scotland, Philip Lymbery, a journalist writing for The Scotsman has turned to his beloved pup Bruce to review Chick Bites dog treats, the...
Breaking nugget news: Japanese scientists create lab-growth chicken with circulatory system
In Tokyo, researchers have created the world’s largest, and most advanced, lab-growth chicken nugget.
Featuring “veins” that deliver nutrients and oxygen, the new nugget...
Be green on the green with biodegradable golf balls
In Vancouver, a company is selling golf balls that biodegrade in two weeks and are made from compressed corn starch, calcium carbonate, glycerin, and...